Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR2 | O95665 | 2/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.40 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.39 |
| ▸ | NRP1 | O14786 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29752649 | 0.90 | NTSR2 (0.43) | NTSR2NTSR1NAALAD2NRP1OPRM1 | |
| SCHEMBL31114334 | 0.87 | OPRM1 (0.55) | NTSR2NTSR1OPRM1CTSB | |
| SCHEMBL30612366 | 0.87 | NAALAD2 (0.44) | NTSR2NTSR1NAALAD2OPRM1CPB2 | |
| SCHEMBL29601866 | 0.84 | OPRM1 (0.51) | NTSR2NTSR1OPRM1 | |
| SCHEMBL31114523 | 0.84 | NRP1 (0.44) | NTSR2NTSR1NAALAD2NRP1OPRM1 | |
| SCHEMBL31114333 | 0.82 | NTSR2 (0.51) | NTSR2NTSR1OPRM1CTSB | |
| SCHEMBL30361658 | 0.82 | NTSR2 (0.43) | NTSR2NTSR1NRP1CTSBCPB2 | |
| SCHEMBL31114385 | 0.81 | OPRM1 (0.57) | NTSR2NTSR1OPRM1 | |
| SCHEMBL31114378 | 0.81 | NAALAD2 (0.45) | NAALAD2NRP1OPRM1CPB2 | |
| SCHEMBL30877896 | 0.81 | NAALAD2 (0.42) | NAALAD2CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665372-A1 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2025-12-24 | — | — | EP | claimed |
| US-20250066417-A9 | NEW PEPTIDE-BASED DIAGNOSTIC AND THERAPEUTIC AGENTS | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2025-02-27 | — | — | US | claimed |
| WO-2024169972-A1 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2024-08-22 | — | — | WO | claimed |
| US-20240182520-A1 | NEW PEPTIDE-BASED DIAGNOSTIC AND THERAPEUTIC AGENTS | ENLITISA SHANGHAI PHARMACEUTICAL CO LTD (CN) | 2024-06-06 | — | — | US | claimed |
| US-20240165247-A1 | NEW PEPTIDE CONJUGATES | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2024-05-23 | — | — | US | claimed |
| US-20240124521-A1 | NEW PEPTIDES | JIANGYIN USUN PHARMACEUTICAL CO., LTD. (CN) | 2024-04-18 | — | — | US | claimed |
| EP-4308167-A1 | NEW PEPTIDE CONJUGATES | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2024-01-24 | — | — | EP | claimed |
| EP-4308584-A1 | NEW PEPTIDE-BASED DIAGNOSTIC AND THERAPEUTIC AGENTS | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2024-01-24 | — | — | EP | claimed |
| CN-117425498-A | Novel peptide conjugates | 艾缇亚(上海)制药有限公司 | 2024-01-19 | — | — | CN | claimed |
| CN-117396491-A | Novel peptide-based diagnostic and therapeutic agents | 艾缇亚(上海)制药有限公司 | 2024-01-12 | — | — | CN | claimed |
| US-20230113836-A1 | NEW CONJUGATES OF PEPTIDES AND POLYSACCHARIDE | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2023-04-13 | — | — | US | claimed |
| EP-4069713-A1 | NEW CONJUGATES OF PEPTIDES AND POLYSACCHARIDE | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2022-10-12 | — | — | EP | claimed |
| WO-2022194239-A1 | NEW PEPTIDE-BASED DIAGNOSTIC AND THERAPEUTIC AGENTS | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2022-09-22 | — | — | WO | claimed |
| WO-2022193186-A1 | NEW DIAGNOSTIC AND THERAPEUTIC AGENTS | JIANGYIN USUN PHARMACEUTICAL CO., LTD. (CN) | 2022-09-22 | — | — | WO | claimed |
| WO-2022193185-A1 | NEW CONJUGATES | JIANGYIN USUN PHARMACEUTICAL CO., LTD. (CN) | 2022-09-22 | — | — | WO | claimed |
| WO-2022194238-A1 | NEW PEPTIDE CONJUGATES | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2022-09-22 | — | — | WO | claimed |
| CN-114929283-A | Novel conjugates of peptides and polysaccharides | 艾缇亚(上海)制药有限公司 | 2022-08-19 | — | — | CN | claimed |
| EP-4028409-A1 | NEW PEPTIDES | Jiangyin Usun Pharmaceutical Co., Ltd. (CN) | 2022-07-20 | — | — | EP | claimed |
| CN-114375298-A | Novel peptides | 江阴贝瑞森制药有限公司 | 2022-04-19 | — | — | CN | claimed |
| US-12612430-B2 | Peptides | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2026-04-28 | — | — | US | disclosed |
| EP-4665372-A1 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2025-12-24 | — | — | EP | disclosed |
| US-20250066417-A9 | NEW PEPTIDE-BASED DIAGNOSTIC AND THERAPEUTIC AGENTS | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2025-02-27 | — | — | US | disclosed |
| WO-2024169972-A1 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2024-08-22 | — | — | WO | disclosed |
| US-20240182520-A1 | NEW PEPTIDE-BASED DIAGNOSTIC AND THERAPEUTIC AGENTS | ENLITISA SHANGHAI PHARMACEUTICAL CO LTD (CN) | 2024-06-06 | — | — | US | disclosed |
| US-20240165247-A1 | NEW PEPTIDE CONJUGATES | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2024-05-23 | — | — | US | disclosed |
| US-20240124521-A1 | NEW PEPTIDES | JIANGYIN USUN PHARMACEUTICAL CO., LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| EP-4308167-A1 | NEW PEPTIDE CONJUGATES | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2024-01-24 | — | — | EP | disclosed |
| EP-4308584-A1 | NEW PEPTIDE-BASED DIAGNOSTIC AND THERAPEUTIC AGENTS | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2024-01-24 | — | — | EP | disclosed |
| CN-117425498-A | Novel peptide conjugates | 艾缇亚(上海)制药有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-117396491-A | Novel peptide-based diagnostic and therapeutic agents | 艾缇亚(上海)制药有限公司 | 2024-01-12 | — | — | CN | disclosed |
| US-20230113836-A1 | NEW CONJUGATES OF PEPTIDES AND POLYSACCHARIDE | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2023-04-13 | — | — | US | disclosed |
| EP-4069713-A1 | NEW CONJUGATES OF PEPTIDES AND POLYSACCHARIDE | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2022-10-12 | — | — | EP | disclosed |
| WO-2022194239-A1 | NEW PEPTIDE-BASED DIAGNOSTIC AND THERAPEUTIC AGENTS | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022193186-A1 | NEW DIAGNOSTIC AND THERAPEUTIC AGENTS | JIANGYIN USUN PHARMACEUTICAL CO., LTD. (CN) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022193185-A1 | NEW CONJUGATES | JIANGYIN USUN PHARMACEUTICAL CO., LTD. (CN) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022194238-A1 | NEW PEPTIDE CONJUGATES | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2022-09-22 | — | — | WO | disclosed |
| CN-114929283-A | Novel conjugates of peptides and polysaccharides | 艾缇亚(上海)制药有限公司 | 2022-08-19 | — | — | CN | disclosed |
| EP-4028409-A1 | NEW PEPTIDES | Jiangyin Usun Pharmaceutical Co., Ltd. (CN) | 2022-07-20 | — | — | EP | disclosed |
| CN-114375298-A | Novel peptides | 江阴贝瑞森制药有限公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-114375298-A | Novel peptides | 江阴贝瑞森制药有限公司 | 2022-04-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113836-A1 | NEW CONJUGATES OF PEPTIDES AND POLYSACCHARIDE | DSG1, HBG1, IDUA | NTSR2 3899/4885NTSR1 3426/4885NAALAD2 709/4885 |
| US-20250066417-A9 | NEW PEPTIDE-BASED DIAGNOSTIC AND THERAPEUTIC AGENTS | NGLY1, YBX1, VIP | NTSR2 1057/4885NTSR1 892/4885NAALAD2 597/4885 |
| US-20240182520-A1 | NEW PEPTIDE-BASED DIAGNOSTIC AND THERAPEUTIC AGENTS | NGLY1, YBX1, VIP | NTSR2 1057/4885NTSR1 892/4885NAALAD2 597/4885 |
| US-12612430-B2 | Peptides | CUTA, VIP, COL14A1 | NTSR2 1049/4885NTSR1 1080/4885NAALAD2 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.